{"transactions":[{"id":921525,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Stock  Option  (Right to  Buy)","published_at":"2026-02-03T19:46:07.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.24,"expiration_date":"2026-12-08","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-036268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000119312526036268/ownership.xml","form_type":"4"}},{"id":921524,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T19:46:07.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":99517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":99517},"source":{"system":"sec-edgar","filing":"0001193125-26-036268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000119312526036268/ownership.xml","form_type":"4"}},{"id":921523,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T19:46:07.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":173466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":173466},"source":{"system":"sec-edgar","filing":"0001193125-26-036268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000119312526036268/ownership.xml","form_type":"4"}},{"id":921522,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2026-02-03T19:46:07.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":1.24,"value":372000.0,"ownership":{"direct":true},"balance_after":767830,"source":{"system":"sec-edgar","filing":"0001193125-26-036268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000119312526036268/ownership.xml","form_type":"4"}},{"id":921521,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2026-02-03T19:46:07.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":106093,"price":4.24,"value":449834.32,"ownership":{"direct":true},"balance_after":467830,"source":{"system":"sec-edgar","filing":"0001193125-26-036268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000119312526036268/ownership.xml","form_type":"4"}},{"id":921520,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2026-02-03T19:46:07.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":272983,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":573923,"source":{"system":"sec-edgar","filing":"0001193125-26-036268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000119312526036268/ownership.xml","form_type":"4"}},{"id":1284391,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T18:00:09.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029."}],"balance_after":440000,"derivative":{"exercise_price":3.06,"expiration_date":"2035-01-30","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0000950170-25-013846","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017025013846/ownership.xml","form_type":"4"}},{"id":1284390,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T18:00:09.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":99518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":99518,"derivative":{"underlying":"Common Stock","underlying_shares":99518},"source":{"system":"sec-edgar","filing":"0000950170-25-013846","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017025013846/ownership.xml","form_type":"4"}},{"id":1284389,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T18:00:09.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":false,"shares":173467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026."}],"balance_after":173466,"derivative":{"underlying":"Common Stock","underlying_shares":173467},"source":{"system":"sec-edgar","filing":"0000950170-25-013846","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017025013846/ownership.xml","form_type":"4"}},{"id":1284388,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2025-02-04T18:00:09.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":88601,"price":3.06,"value":271119.06,"ownership":{"direct":true},"balance_after":300940,"source":{"system":"sec-edgar","filing":"0000950170-25-013846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017025013846/ownership.xml","form_type":"4"}},{"id":1284387,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2025-02-04T18:00:09.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":99517,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units (\"PSUs\")."}],"balance_after":389541,"source":{"system":"sec-edgar","filing":"0000950170-25-013846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017025013846/ownership.xml","form_type":"4"}},{"id":1284386,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2025-02-04T18:00:09.000Z","date":"2025-01-31","kind":"exercise","planned":false,"acquired":true,"shares":173467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":290024,"source":{"system":"sec-edgar","filing":"0000950170-25-013846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017025013846/ownership.xml","form_type":"4"}},{"id":1402246,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2024-09-19T20:02:31.000Z","date":"2024-09-19","kind":"sale","planned":true,"acquired":false,"shares":1841,"price":4.0019,"value":7367.4979,"ownership":{"direct":false,"nature":"Held by JPM Partners LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5866025,"source":{"system":"sec-edgar","filing":"0000950170-24-108233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024108233/ownership.xml","form_type":"4"}},{"id":1402245,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2024-09-19T20:02:31.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":22187,"price":4.0325,"value":89469.0775,"ownership":{"direct":false,"nature":"Held by JPM Partners LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5867866,"source":{"system":"sec-edgar","filing":"0000950170-24-108233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024108233/ownership.xml","form_type":"4"}},{"id":1402244,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2024-09-19T20:02:31.000Z","date":"2024-09-17","kind":"sale","planned":true,"acquired":false,"shares":33941,"price":4.0458,"value":137318.4978,"ownership":{"direct":false,"nature":"Held by JPM Partners LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":5890053,"source":{"system":"sec-edgar","filing":"0000950170-24-108233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024108233/ownership.xml","form_type":"4"}},{"id":1486539,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2024-06-07T18:34:21.000Z","date":"2024-06-05","kind":"sale","planned":true,"acquired":false,"shares":1006,"price":4,"value":4024.0,"ownership":{"direct":false,"nature":"Held by JPM Partners LLC"},"balance_after":5923994,"source":{"system":"sec-edgar","filing":"0000950170-24-070965","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024070965/ownership.xml","form_type":"4"}},{"id":1661341,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:30:44.000Z","date":"2024-01-31","kind":"grant","planned":true,"acquired":true,"shares":448000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028."}],"balance_after":448000,"derivative":{"exercise_price":4.16,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":448000},"source":{"system":"sec-edgar","filing":"0000950170-24-010972","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024010972/ownership.xml","form_type":"4"}},{"id":1661340,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Restricted Stock Units","published_at":"2024-02-02T21:30:44.000Z","date":"2024-01-31","kind":"exercise","planned":true,"acquired":false,"shares":173467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026."}],"balance_after":346933,"derivative":{"underlying":"Common Stock","underlying_shares":173467},"source":{"system":"sec-edgar","filing":"0000950170-24-010972","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024010972/ownership.xml","form_type":"4"}},{"id":1661339,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2024-02-02T21:30:44.000Z","date":"2024-02-01","kind":"sale","planned":true,"acquired":false,"shares":56910,"price":3.845,"value":218818.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated May 18, 2023."}],"balance_after":116557,"source":{"system":"sec-edgar","filing":"0000950170-24-010972","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024010972/ownership.xml","form_type":"4"}},{"id":1661338,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2024-02-02T21:30:44.000Z","date":"2024-01-31","kind":"exercise","planned":true,"acquired":true,"shares":173467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":173467,"source":{"system":"sec-edgar","filing":"0000950170-24-010972","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000095017024010972/ownership.xml","form_type":"4"}},{"id":1972624,"issuer":{"id":115963,"kind":"organization","name":"ABG Acquisition Corp. I","symbol":"ABGI"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B ordinary shares","published_at":"2023-03-03T16:00:37.000Z","date":"2023-03-01","kind":"disposition_to_issuer","acquired":false,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares (\"Class B Shares\") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This Form 4 reflects the surrender to the Issuer of 32,500 Class B Shares for no consideration by the Reporting Person pursuant to the Share Surrender Letter, dated March 1, 2023, by and between the Issuer and the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares (\"Class B Shares\") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares (\"Class B Shares\") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-23-006943","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924323006943/doc4.xml","form_type":"4"}},{"id":2035647,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-02T18:33:14.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":728600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027."}],"balance_after":728600,"derivative":{"exercise_price":4.63,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":728600},"source":{"system":"sec-edgar","filing":"0000899243-23-003615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924323003615/doc4.xml","form_type":"4"}},{"id":2035646,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Restricted Stock Units","published_at":"2023-02-02T18:33:14.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":520400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026."}],"balance_after":520400,"derivative":{"underlying":"Common Stock","underlying_shares":520400},"source":{"system":"sec-edgar","filing":"0000899243-23-003615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924323003615/doc4.xml","form_type":"4"}},{"id":2416214,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-02T17:15:38.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":378033,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022."}],"balance_after":378033,"derivative":{"exercise_price":7.14,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":378033},"source":{"system":"sec-edgar","filing":"0000899243-22-004182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924322004182/doc4.xml","form_type":"4"}},{"id":2649659,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-30T18:49:34.000Z","date":"2021-06-28","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option shall vest on 6/28/2022, subject to Reporting Person continuing to provide service through such date."}],"balance_after":26000,"derivative":{"exercise_price":5.59,"expiration_date":"2031-06-27","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-21-044091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919121044091/doc4.xml","form_type":"4"}},{"id":2888429,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T16:56:56.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":640000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021."}],"balance_after":640000,"derivative":{"exercise_price":73,"expiration_date":"2031-01-28","underlying":"Common Stock","underlying_shares":640000},"source":{"system":"sec-edgar","filing":"0000899243-21-003873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924321003873/doc4.xml","form_type":"4"}},{"id":2994517,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-11-03T20:08:25.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":750000,"ownership":{"direct":false,"nature":"Held by JPM Partners LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000899243-20-030329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924320030329/doc4.xml","form_type":"4"}},{"id":2994516,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, and Chairman"}}],"security":"Common Stock","published_at":"2020-11-03T20:08:25.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":750000,"ownership":{"direct":false,"nature":"Held by JPM Partners LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock."}],"balance_after":5925000,"source":{"system":"sec-edgar","filing":"0000899243-20-030329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000089924320030329/doc4.xml","form_type":"4"}},{"id":3098371,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T17:09:46.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":8896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option shall vest on 6/24/2021, subject to Reporting Person continuing to provide service through such date."}],"balance_after":8896,"derivative":{"exercise_price":5.6,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":8896},"source":{"system":"sec-edgar","filing":"0001209191-20-039113","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919120039113/doc4.xml","form_type":"4"}},{"id":3476817,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-27T18:54:19.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":8896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option shall vest on 6/25/2020, subject to Reporting Person continuing to provide service through such date."}],"balance_after":8896,"derivative":{"exercise_price":7.63,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":8896},"source":{"system":"sec-edgar","filing":"0001209191-19-039356","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919119039356/doc4.xml","form_type":"4"}},{"id":3882159,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Perferred Stock","published_at":"2018-06-27T16:54:46.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":35258,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By JPM Partners, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":35258},"source":{"system":"sec-edgar","filing":"0001209191-18-039678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919118039678/doc4.xml","form_type":"4"}},{"id":3882158,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Perferred Stock","published_at":"2018-06-27T16:54:46.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":52581,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By JPM Partners, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":52581},"source":{"system":"sec-edgar","filing":"0001209191-18-039678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919118039678/doc4.xml","form_type":"4"}},{"id":3882157,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T16:54:46.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":35258,"ownership":{"direct":false,"nature":"By JPM Partners, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."}],"balance_after":178440,"source":{"system":"sec-edgar","filing":"0001209191-18-039678","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919118039678/doc4.xml","form_type":"4"}},{"id":3882156,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":67945,"kind":"person","name":"Sommadossi Jean-Pierre","position":1,"cik":"0001296995","reported_name":"Sommadossi Jean-Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T16:54:46.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":52581,"ownership":{"direct":false,"nature":"By JPM Partners, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."}],"balance_after":143182,"source":{"system":"sec-edgar","filing":"0001209191-18-039678","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296995/000120919118039678/doc4.xml","form_type":"4"}}]}